04/16/2026
Big news in peptide medicine today, and we’ve been waiting for this moment for a long time.
The FDA officially announced the removal of 12 peptides from its Category 2 “Do Not Compound” list. Secretary Kennedy said it plainly: the 2023 restrictions drove a dangerous black market that put Americans at risk. Today’s action begins to restore regulated, physician supervised access.
Here’s what’s actually happening:
→ 12 peptides are now moving toward formal PCAC review
→ Advisory committee meetings begin July 2026
→ Final access decisions expected 2026 to 2027
→ Public comments open through July 9 at regulations.gov
The full list: BPC 157 · TB 500 · KPV · MOTS C · GHK Cu (injectable) · Semax · Epitalon · DSIP/Emideltide · DiHexa · Ibutamoren · LL 37 · Melanotan II
What this is NOT: FDA approval. These remain off label therapeutics. A valid prescription, licensed compounding pharmacy, baseline labs, and clinical oversight are still non negotiable. The pathway is opening, but how you walk through it matters enormously.
Three things every patient should evaluate before trusting anyone with peptide therapy: provider credentials and training, pharmacy sourcing quality, and responsible clinical oversight. We built OneLife around all three.
We’ve been prescribing peptide therapy since 2016, before it was mainstream, through the 2023 restrictions, and now into this new chapter. We’ve trained other providers nationally, spoken at medical conferences on peptide medicine, and spent nearly a decade building clinical protocols grounded in labs, biomarker tracking, and individual biology. We use peptides as a precision tool to reverse disease and optimize human performance. Not a trend. Not a product. A clinical discipline.
The demand for safe, regulated peptide therapy never went away. It just went underground. Now there’s a legitimate path forward, and we have the team, the protocols, and the experience to deliver it at the highest level!
If you’ve been waiting to do this the right way, we’re ready.
📞 Call us at 561-327-9393 to schedule a consultation.